Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Dermatol Clin. 2012 Oct;30(4):643-56, vi. doi: 10.1016/j.det.2012.06.005. Epub 2012 Aug 11.

Fibrous and fibrohistiocytic neoplasms: an update.

Author information

  • 1Department of Pathology, Penn State Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA. lclarke@hmc.psu.edu

Abstract

Important advances in fibroblastic and fibrohistiocytic tumors relevant to dermatologists and dermatopathologists include (1) recognition that myxofibrosarcoma is a distinct entity that frequently arises in skin; (2) CD10 is sensitive but not specific atypical fibroxanthoma; (3) neurothekeomas lacking S100 expression are probably fibrohistiocytic/fibroblastic tumors, whereas S100+ myxoid variants are better classified as nerve sheath myxomas; (4) the recognition of a primary cutaneous variant of solitary fibrous tumor; (5) thelimitations of b-catenin immunohistochemistry in desmoid tumors; and (6) the prognostic utility of clinical and histopathologic variables in dermatofibrosarcoma protuberans, and the effects of imatinib mesylate therapy.

Copyright © 2012. Published by Elsevier Inc.

PMID:
23021051
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk